Amber Tong

4 days ago | news.bloomberglaw.com | Phoebe Sedgman |Amber Tong |Ashleigh Furlong

Sanofi agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the French drugmaker expands further in rare immunological diseases. Sanofi will pay $129 per share in cash for the US biotech, it said in a statement. That represents a 27% premium to Blueprint’s closing price on Friday. The pharmaceutical firm has touted its ambition to become an immunology powerhouse, and earlier this year it clinched a pact to buy a promising antibody drug for up to $1.9 billion.

4 days ago | bloomberglinea.com.br | Phoebe Sedgman |Amber Tong |Ashleigh Furlong |Seong Joon Cho

Bloomberg — A Sanofi concordou em comprar a Blueprint por pelo menos US$ 9,1 bilhões, à medida que a farmacêutica francesa se expande ainda mais em doenças imunológicas raras. A Sanofi pagará US$ 129 por ação pela biotecnologia americana, informou em um comunicado. Isso representa um prêmio de 27% sobre o preço de fechamento da Blueprint na sexta-feira.

4 days ago | news.bloombergtax.com | Phoebe Sedgman |Amber Tong |Ashleigh Furlong

Sanofi SA agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the French drugmaker further expands its rare immunological disease portfolio. Sanofi will pay $129 per share in cash for the US biotech, it said in a statement. That represents a 27% premium to Blueprint’s closing price on Friday. Sanofi has touted its ambition to become an immunology powerhouse, and earlier this year it clinched a pact to buy a promising antibody drug for up to $1.9 billion.

4 days ago | bloomberg.com | Phoebe Sedgman |Amber Tong |Ashleigh Furlong

Laboratory research. Photographer: SeongJoon Cho/Bloomberg(Bloomberg) -- Sanofi agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the French drugmaker expands further in rare immunological diseases. Sanofi will pay $129 per share in cash for the US biotech, it said in a statement. That represents a 27% premium to Blueprint’s closing price on Friday.

2 weeks ago | news.bloomberglaw.com | Amber Tong

Jiangsu Hengrui Pharmaceuticals Co., China’s largest drugmaker by market value, surged in its trading debut in Hong Kong after raising HK$9.9 billion ($1.3 billion) as listings pick up in the Asian financial hub. The stock jumped 25% to HK$55.15 on Friday. Ahead of the debut, the company had sold its stock at the top end of the marketed range amid strong demand for the shares.